225 related articles for article (PubMed ID: 34424450)
1. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Sears TK; Horbinski CM; Woolard KD
J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
[TBL] [Abstract][Full Text] [Related]
2. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
[TBL] [Abstract][Full Text] [Related]
3. EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.
Sprinzen L; Garcia F; Mela A; Lei L; Upadhyayula P; Mahajan A; Humala N; Manier L; Caprioli R; Quiñones-Hinojosa A; Casaccia P; Canoll P
Cells; 2024 Jan; 13(3):. PubMed ID: 38334611
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
7. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
8. Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level.
Dekker LJM; Wu S; Jurriëns C; Mustafa DAN; Grevers F; Burgers PC; Sillevis Smitt PAE; Kros JM; Luider TM
FASEB J; 2020 Mar; 34(3):3646-3657. PubMed ID: 31960518
[TBL] [Abstract][Full Text] [Related]
9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
10. Mutant IDH1 and seizures in patients with glioma.
Chen H; Judkins J; Thomas C; Wu M; Khoury L; Benjamin CG; Pacione D; Golfinos JG; Kumthekar P; Ghamsari F; Chen L; Lein P; Chetkovich DM; Snuderl M; Horbinski C
Neurology; 2017 May; 88(19):1805-1813. PubMed ID: 28404805
[TBL] [Abstract][Full Text] [Related]
11. Large-Scale Drug Screening in Patient-Derived IDH
Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
[TBL] [Abstract][Full Text] [Related]
12. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
14. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
15. Non-Invasive Estimation of Glioma
Hu Y; Chen Y; Wang J; Kang JJ; Shen DD; Jia ZZ
Front Oncol; 2020; 10():593102. PubMed ID: 33425744
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
17. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.
Dow J; Krysztofiak A; Liu Y; Colon-Rios DA; Rogers FA; Glazer PM
Mol Cancer Res; 2021 Dec; 19(12):2057-2067. PubMed ID: 34535560
[TBL] [Abstract][Full Text] [Related]
18. Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
Hu Y; Zhang N; Yu MH; Zhou XJ; Ge M; Shen DD; Hua Y; Shi JL; Jia ZZ
Eur J Radiol; 2020 Oct; 131():109247. PubMed ID: 32891974
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]